Reuters logo
BRIEF-Agenus up 27.5 percent premarket after phase 2 results for brain cancer vaccine
December 16, 2013 / 1:20 PM / 4 years ago

BRIEF-Agenus up 27.5 percent premarket after phase 2 results for brain cancer vaccine

NEW YORK, Dec 16 (Reuters) - Agenus Inc : * Up 27.5 percent to $3.11 in premarket after phase 2 results for brain cancer vaccine

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below